Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. - Wikidata - awgldk - TriplyDB

Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.

Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.

http://www.wikidata.org/entity/Q44068570

about

Chronic hepatitis C: This and the new era of treatment New treatment strategies for hepatitis C infection Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests Genetic variability in CYP3A5 and its possible consequences.Structural features of cytochromes P450 and ligands that affect drug metabolism as revealed by X-ray crystallography and NMR.Contributions of human enzymes in carcinogen metabolism A re-evaluation and validation of ontogeny functions for cytochrome P450 1A2 and 3A4 based on in vivo data.Prediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability.Evaluation of CYP3A activity in humans using three different parameters based on endogenous cortisol metabolism.Nifedipine pharmacokinetics are influenced by CYP3A5 genotype when used as a preterm labor tocolytic Colonization-induced host-gut microbial metabolic interaction Effect of pharmacogenetics on plasma lumefantrine pharmacokinetics and malaria treatment outcome in pregnant women Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver.Reduced methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with CYP3A5*3 allele or a change in diet composition.Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone.Sulforaphane: translational research from laboratory bench to clinic.Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics.An integrated pharmacokinetics ontology and corpus for text mining.Inter-individual variation in midazolam clearance in children.Metabolic capabilities of cytochrome P450 enzymes in Chinese liver microsomes compared with those in Caucasian liver microsomes.Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models Expression and regulation of human fetal-specific CYP3A7 in mice CYP3A5 phenotype-genotype correlations in a British population.A new CYP3A5 variant, CYP3A5*11, is shown to be defective in nifedipine metabolism in a recombinant cDNA expression system.Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans.Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms.Importance of patient selection when determining the significance of the CYP3A5 polymorphism in clinical trials.Cytochrome P450 3A polymorphisms and immunosuppressive drugs.Clinical implications of CYP3A polymorphisms.Cell-based models to study hepatic drug metabolism and enzyme induction in humans.Pharmacogenomics of Cytochrome P450 3A4: Recent Progress Toward the "Missing Heritability" Problem Concurrent assessment of hepatic and intestinal cytochrome P450 3A activities using deuterated alfentanil Midazolam metabolism in cytochrome P450 3A knockout mice can be attributed to up-regulated CYP2C enzymes Comparison of CYP3A4 and CYP3A5: the effects of cytochrome b5 and NADPH-cytochrome P450 reductase on testosterone hydroxylation activities Discordant associations between SLCO1B1 521T→C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146.A Semi-Mechanistic Metabolism Model of CYP3A Substrates in Pregnancy: Predicting Changes in Midazolam and Nifedipine Pharmacokinetics.Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines.A pharmacogenomics primer.Meconium Atazanavir Concentrations and Early Language Outcomes in HIV-Exposed Uninfected Infants With Prenatal Atazanavir Exposure.Drugs as CYP3A probes, inducers, and inhibitors.

P2860

Q26775011-FC855965-B609-4741-82BC-78FE0589D7C7 Q26795407-5D022A68-DEC2-44C8-BC5C-3E5FA7DA49C0 Q28260518-3D4D0C48-E1A1-4A7A-B3E3-C8C73A0C0048 Q30341330-ED57DF17-121B-418B-92DC-2F1328883B36 Q30396630-68E57B0F-FDD1-450D-AE41-8DCDD12421CD Q30520640-58C74189-74FA-4C5C-BFBE-F088E775368C Q30786488-6C08D223-1C85-4FC9-A25F-E6BA54E6D8AE Q31044030-A6B749B0-510B-4A7D-AAE1-27F747798A45 Q33555015-55398345-4ED3-4656-B0B7-8EECE1340B5F Q33688800-9DEA6230-F878-4455-B7A1-DF054F062EBC Q33833363-F77E18F6-BAA4-4EE9-AB79-5D075F87A499 Q33869119-565F7A84-CB04-4C23-A92F-68C4E126F60A Q34018308-6BC1A704-CCD1-4D95-BABE-73E70153EB47 Q34278794-580DE1D5-1893-40FB-B342-59E2E15E7C9D Q34290581-B8B7F8CC-C1A2-498B-B815-7B5C0BE1D7DF Q34379434-908419FF-9D96-447F-AC35-70092D1D3FF7 Q34563883-9589A528-2909-492E-9B7E-D24E6270B07C Q34572334-F9287CAA-E11E-40EB-8117-DF9DA2B653BC Q35301181-935EA848-0E19-457D-947B-DCCBCAB91B8C Q35718630-56F0351C-5583-4378-96D2-150E8808AD15 Q35753588-62DA74D9-7007-4FEB-A60F-09D088DCFA3C Q35762696-5097B23D-45C0-44DC-B585-089437953E28 Q35825323-9200B203-E1C8-4B70-8BE0-38DF11E3484B Q35826448-75A0B949-DFF7-4803-972A-9193EA245008 Q35863379-DCF7EBA9-7BA0-44ED-AB8B-405A94F765ED Q35876954-243D6F30-AAC0-4247-BBC3-7B6EBED23056 Q35918055-939115DC-AF36-4372-A86E-0F3AA5A74999 Q36050572-22031C6D-459B-4EFC-A80F-1665EAF69258 Q36546247-68BDDC0B-0206-4B47-B627-D3F4208394BF Q36572634-EB6C9DB6-AC10-4110-9573-DD6E69D7744A Q36634077-1D8ADC88-6015-47FA-B175-99B739E773AF Q36646017-B4CC93BB-AE25-48B0-A075-0715B352FC82 Q36667359-2C241D6D-F5FC-4A43-82A8-6063C1B8A3CE Q36700755-255D90FE-2C7D-4ED1-9E0F-164005E75ED7 Q36701911-7C45958F-FA6B-4A30-9256-C437FEF48458 Q36702463-BE677FCF-9576-490A-9433-994D485AB940 Q36884097-C7EE4886-472B-4346-AF81-5991D03FE509 Q36896796-AA91BB55-5390-4E98-A279-707B11BAC571 Q36951911-96D8E7A5-603A-4F3D-B642-450E3DD933FD Q37023996-4C427AF8-E2DB-4C0C-A456-5BA62022103C

P2860

Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.

http://www.wikidata.org/entity/Q44068570

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh

2002年學術文章

@zh-hant

name

Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.

@en

Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.

@nl

type

label

Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.

@en

Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.

@nl

prefLabel

Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.

@en

Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.

@nl

P1433

Q44068570-684DA5B7-1D19-4023-A832-8066506EFE85

P1476

Q44068570-21EF0E28-7796-4AA9-B94B-9867AD94F071

P2093

Q44068570-07B51F02-D0E3-47AE-93CF-B7E911029A21

Q44068570-2C08927C-6CC5-453D-ADC4-439F0CD11A7A

Q44068570-3DD2DDF6-318B-4E48-BF9B-459033F4EF6D

Q44068570-3F3E20C9-2F51-4A0F-A8C3-CDAAF335B362

Q44068570-5EDD0CA4-A807-4791-9AE5-0E40701C46B5

Q44068570-7743CE62-FA58-4979-BCF5-319124769854

Q44068570-9E495550-7D62-4BFF-A942-74B046D4109C

Q44068570-B8BFAB72-C7F8-4A44-86F5-150C02816452

Q44068570-C1AD0703-DF92-4E73-BF77-FD76C70AD79D

P304

Q44068570-303FBC1F-D1E0-416E-9DB5-38B9D649E49A

P31

Q44068570-D0B0439E-7C11-4548-890E-8F6AE84DCBF5

P356

Q44068570-8BECC4EE-59B4-44CB-8560-6057DAD1FF25

P433

Q44068570-2B437173-3E7E-45F1-AF32-79DA05B90AFB

P478

Q44068570-903BDE41-ECDB-43C6-947F-0CF93D16C58D

P577

Q44068570-E299C378-7A6C-4D8C-BABA-E2BC9C703679

P5875

Q44068570-206100EF-2852-4CF7-916D-00988FD86063

P698

Q44068570-0055CDB9-3C9D-47B1-A004-B946034B40B8

P356

P1433

Drug Metabolism and Disposition

P1476

Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.

@en

P2093

Barbara J Ring

http://www.w3.org/2001/XMLSchema#string

David R Jones

http://www.w3.org/2001/XMLSchema#string

J Andrew Williams

http://www.w3.org/2001/XMLSchema#string

James Eckstein

http://www.w3.org/2001/XMLSchema#string

Kenneth Ruterbories

http://www.w3.org/2001/XMLSchema#string

Mitchell A Hamman

http://www.w3.org/2001/XMLSchema#string

Stephen D Hall

http://www.w3.org/2001/XMLSchema#string

Steven A Wrighton

http://www.w3.org/2001/XMLSchema#string

Varon E Cantrell

http://www.w3.org/2001/XMLSchema#string

P304

883-891

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1124/DMD.30.8.883

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P577

2002-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273580705

http://www.w3.org/2001/XMLSchema#string

P698

12124305

http://www.w3.org/2001/XMLSchema#string